1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037


Delayed Nasdaq  -  04:00 2022-06-27 pm EDT
213.57 USD   +0.77%
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm

05/03/2022 | 07:10am EDT
FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo

May 3 (Reuters) - Biogen Inc said on Tuesday that chief executive Michel Vounatsos will step down and that the company is pulling back on selling its controversial Alzheimer's drug Aduhelm, in what appears to be a final blow to its prospect of becoming a big seller.

The future of Aduhelm has been in doubt since the U.S. government's Medicare program restricted coverage of the medicine to patients in clinical trials.

Aduhelm was expected to be the company's next big blockbuster treatment, but controversy over its approval without clear evidence of patient benefit and the U.S. decision to severely limit access cast serious doubt on its sales potential.

Biogen said on Tuesday https://bit.ly/3LHu8vF it was looking at "substantially" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in addition to the current program to save $500 million annually.

Biogen last month decided to withdraw its marketing application for Aduhelm in Europe after failing to convince the European regulator of the treatment's benefits.

The company said it will retain minimal resources to make Aduhelm available to patients currently taking the drug in the United States.

Vounatsos, who was named as the CEO in 2016, will continue in his role until a successor is appointed, the company said. Under his leadership, the U.S. biotech developed and launched several important growth drivers including spinal muscular atrophy drug Spinraza and multiple sclerosis drug Vumerity.

"The news (about Vounatsos) is not surprising, given the many setbacks the company has faced," said RBC Capital Markets analyst Brian Abrahams, adding that it "may help add to the perception that Biogen will turn the page from being overly levered to Alzheimer's to assembling a more diverse pipeline."

Biogen shares were up about 1.3% at $210.03 on Tuesday. The stock is down 47% since Aduhelm was approved in June.

The company was betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to act as a buffer as its main established revenue drivers face rising competition.

The U.S. Food and Drug Administration approved the treatment last June despite a lack of clear evidence that it slowed cognitive decline and over objections of the agency's panel of outside expert advisers.

Aduhelm had sales of just $2.8 million in the first quarter, missing analysts' diminished estimates. The company said its earnings were hit by a $275 million Aduhelm inventory write-off.

Excluding items, Biogen earned $4.38 per share, in line with analysts' estimates.

Vounatsos called the setbacks faced by the company in the last 12 months "significant," but said Biogen remained committed to Alzheimer’s disease.

Biogen is still counting on a second Alzheimer's drug, lecanemab which, like Aduhelm, was developed with Japanese company Eisai Co. Ltd.

Biogen plans to complete a rolling submission of data for lecanemab under the U.S. accelerated approval pathway in the current quarter before submitting it for full approval in 2023.

On Tuesday, Eisai revised down its operating profit forecast for the year ended March 31 by 31.4% to 53.5 billion yen ($411 million), citing the impact of the U.S. coverage policy for Aduhelm. ($1 = 130.1300 yen)

(Reporting by Leroy Leo and Mrinalika Roy in Bengaluru; Additional reporting by Makiko Yamazaki in Tokyo; Editing by Shounak Dasgupta and Bill Berkrot)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.77% 213.57 Delayed Quote.-11.67%
EISAI CO., LTD. 1.06% 5595 Delayed Quote.-14.85%
All news about BIOGEN INC.
06/24Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index
06/24BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Index
06/24BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Index
06/22Biogen, Happify Health Team Up to Offer Digital Services for Multiple Sclerosis Patient..
06/22Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar..
06/22Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital..
06/22Biogen and Happify Health Collaborates to Support Multiple Sclerosis Patients on Digita..
06/21BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote o..
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2022 9 831 M - -
Net income 2022 1 994 M - -
Net cash 2022 60,0 M - -
P/E ratio 2022 15,2x
Yield 2022 -
Capitalization 31 278 M 31 278 M -
EV / Sales 2022 3,18x
EV / Sales 2023 2,98x
Nbr of Employees 9 610
Free-Float 85,5%
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 213,57 $
Average target price 242,78 $
Spread / Average Target 13,7%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Alphonse Galdes EVP-Pharmaceutical Operations & Technology
Mahalakshmi Radhakrishnan Chief Medical Officer & Group Senior VP
Sector and Competitors
1st jan.Capi. (M$)
BIOGEN INC.-11.67%31 038
CSL LIMITED-6.70%90 814
UCB-19.34%16 152